低剂量贝利尤单抗降低系统性红斑狼疮患者疾病复发风险
这项多中心随机双盲安慰剂对照试验评估低剂量贝利尤单抗在低疾病活动度中国系统性红斑狼疮患者中预防疾病复发的疗效。52周内贝利尤单抗组疾病复发率7.8%,显著低于安慰剂组19.1%(P=.012)。贝利尤单抗总体耐受性良好。
要点
- 低剂量贝利尤单抗组疾病复发率7.8%,显著低于安慰剂组19.1%(P=.012)。
- Kaplan-Meier曲线显示贝利尤单抗组累积复发率更低(P=.011,HR 0.38,95%CI 0.17-0.83)。
- 两组不良事件发生率相当(61.2% vs 64.3%),严重不良事件分别为4例(3.4%)和6例(5.2%)。
核心结论
- 低剂量贝利尤单抗有助于降低低疾病活动度中国系统性红斑狼疮患者的疾病复发风险,且总体耐受性良好。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验(NCT04515719),52周疗程;因上海封控期间仁济医院被指定为COVID-19定点医院于2022年4月10日提前终止。
- 纳入SELENA-SLEDAI评分≤6、BILAG无A且≤1个B、筛查时泼尼松≤20 mg/d的患者,按1:1随机分配至静脉120 mg贝利尤单抗组(n=116)或安慰剂(生理盐水)组(n=115)。
- 主要终点为52周内疾病复发;贝利尤单抗组90.5%、安慰剂组86.1%的患者在31±16.1周随访内完成研究。
主要发现
- 贝利尤单抗组7.8%的患者发生疾病复发,显著低于安慰剂组的19.1%(P=.012;差值11.3%;95%CI 1.8%-20.9%)。
- Kaplan-Meier曲线显示贝利尤单抗组累积复发率更低(P=.011,HR 0.38;95%CI 0.17-0.83)。
- 激素节约效应两组相当(泼尼松较基线变化:贝利尤单抗组-1.55±10.11 mg/d vs 安慰剂组-0.91±7.43 mg/d,P=.075)。
- SELENA-SLEDAI在贝利尤单抗组降低0.62±2.14,而安慰剂组升高0.12±2.80(P=.009)。
- 任何不良事件两组相当(贝利尤单抗组61.2% vs 安慰剂组64.3%);严重不良事件分别为4例(3.4%)和6例(5.2%)。
关键数值与推荐
- 主要终点达标:贝利尤单抗组复发率7.8% vs 安慰剂组19.1%(P=.012;差值11.3%;95%CI 1.8%-20.9%)。
- Kaplan-Meier累积复发率:贝利尤单抗组低于安慰剂组(P=.011,HR 0.38;95%CI 0.17-0.83)。
- SELENA-SLEDAI变化:贝利尤单抗组-0.62±2.14 vs 安慰剂组+0.12±2.80(P=.009)。
- 泼尼松较基线变化:贝利尤单抗组-1.55±10.11 mg/d vs 安慰剂组-0.91±7.43 mg/d(P=.075)。
临床怎么用
- 对于低疾病活动度(SELENA-SLEDAI≤6、BILAG无A且≤1个B、泼尼松≤20 mg/d)的中国系统性红斑狼疮患者,静脉低剂量贝利尤单抗(120 mg)可考虑用于降低疾病复发风险。
局限性
- 试验因上海封控期间仁济医院被指定为COVID-19定点医院于2022年4月10日提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The efficacy of low-dose belimumab for disease flare prevention in patients with lupus with low disease activity was evaluated (NCT04515719). METHODS: In this 52-week, randomised, placebo-controlled trial, patients who had a Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of ≤6, with no A and ≤ 1 B on British Isles Lupus Assessment Group, and who had prednisone ≤20 mg/d at screening were enrolled and randomly assigned 1:1 to intravenous 120 mg belimumab or placebo (saline). The primary outcome was disease flares within 52 weeks. The trial was terminated prematurely on 10 April 2022 when Renji Hospital was designated as a COVID-19 referral centre during the Shanghai lockdown. RESULTS: Overall, 90.5% and 86.1% of patients in the belimumab (n = 116) and placebo (n = 115) arms completed the study within a follow-up of 31 ± 16.1 weeks. The primary endpoint was met. In total, 7.8% of patients receiving low-dose belimumab had disease flares, significantly lower than that in the placebo group (19.1%) (P = .012; difference 11.3%; 95% CI 1.8%-20.9%). Kaplan-Meier curves also demonstrated lower cumulative flare rates in the belimumab arm (P = .011, Hazard Ratio (HR), 0.38; 95% CI 0.17-0.83). Glucocorticoid-sparing effects were comparable (Δprednisone from baseline, -1.55 ± 10.11 mg/d vs -0.91 ± 7.43 mg/d, P = .075). SELENA-SLEDAI was reduced by 0.62 ± 2.14 in the belimumab group; however, it increased by 0.12 ± 2.80 in the placebo group (P = .009). Any adverse events were comparable (61.2% vs 64.3%). Only 4 (3.4%) and 6 (5.2%) severe adverse events occurred in 2 groups, respectively. CONCLUSIONS: Treatment with low-dose belimumab helped reduce the risks of disease flares in Chinese patients with systemic lupus erythematosus at low disease activity. Belimumab was generally well-tolerated.
引用
- Sun F, Wang H, Zhang D, et al. Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2025. PMID: 41203461. doi:10.1016/j.ard.2025.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。